/PRNewswire/ J INTS BIO announced that the preclinical results of "JIN-A04," a novel oral tyrosine kinase inhibitor (TKI) targeting HER2 Exon20 insertion.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 12, 2022 ORIC Pharmaceuticals, Inc. , a clinical stage oncology company focused on developing treatments that address mechanisms of. | April 12, 2022
The princess, born Micaëla Ana María Cousiño y Quiñones de León in Vichy in central France in 1938, into a family of Chilean-Spanish nobles, passed away on Sunday.